TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16226211

Group type: EXPERIMENTAL
Intervention: Operating the vehicle entertainment system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conducting a simulated hands-free mobile phone conversation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex highway environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple highway environment
Number of subjects: 0
Study: 14515185

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) at 24 microg/kg/h (N=850)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Placebo (N=840)
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690
Study: 10861916

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 3.7 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional antipsychotic agents (historical control)
Number of subjects: 180
Study: 9032177

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asthma and COPD
Number of subjects: 0
Study: 7801579

Group type: EXPERIMENTAL
Intervention: Bengal rose stain labeled with short‐lived 123I (123I‐BR)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Higher activities of 123I‐BR (120 MBc and higher)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Single complex radionuclide examination
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Presence of hyperbilirubinemia
Number of subjects: 201
Study: 2874825

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 or 40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31636828

Group type: EXPERIMENTAL
Intervention: Psychopharmacotherapy‐Structured Clinical Observation (P‐SCO)
Number of subjects: 65
Study: 28436580

Group type: EXPERIMENTAL
Intervention: Rescue antenatal steroids (AS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 24495273

Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride orally disintegrating tablet (ODT) with 10 mg of ammonium glycyrrhizinate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride ODT with 50% Starlac®
Number of subjects: 16
Study: 24398166

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB) program for 14 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB) program
Number of subjects: 46
Study: 22513296

Group type: EXPERIMENTAL
Intervention: Obesity risk alleles at FTO rs1421085
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Risk variants within BDNF
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Risk allele at SH2B1 rs4788099
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Risk allele at TNNI3K rs1514176
Number of subjects: 2075
Study: 19365775

Group type: EXPERIMENTAL
Intervention: Asphalt workers
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study: 17563023

Group type: EXPERIMENTAL
Intervention: Simultaneous counseling (1 in-clinic session on all 3 behaviors every 6 months, supplemented by motivational interviewing by telephone for 18 months)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Sequential counseling (addressing a new behavior every 6 months)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Usual care (1-time referral to existing group classes)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Simultaneous counseling
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Sequential counseling
Number of subjects: 289

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 289
Study: 12719667

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (group A)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Topical norfloxacin (group B)
Number of subjects: 190
Study: 11094369

Group type: EXPERIMENTAL
Intervention: Maxillary protraction bow appliance
Number of subjects: 29

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 29
Study: 8973975

Group type: EXPERIMENTAL
Intervention: High intensity, short duration (HS) = 70% VO2peak for 15 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low intensity, long duration (LL) = 35% VO2peak for 30 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low intensity, short duration (LS) = 35% VO2peak for 15 min
Number of subjects: 10
Study: 1627281

Group type: EXPERIMENTAL
Intervention: Subdermal needle electrodes (stainless steel and platinum/iridium alloy)
Number of subjects: 19
Study: 6334142

Group type: EXPERIMENTAL
Intervention: RT plus CCNU
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: RT plus CCNU plus LMS
Number of subjects: 31
Study: 3161700

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 302
Study: 29428751

Group type: EXPERIMENTAL
Intervention: Fermented milk with Lactococcus lactis NRRL B‐50571
Number of subjects: 36

Group type: COMPARATOR
Intervention: Artificially acidified milk (Control)
Number of subjects: 36
Study: 27724870

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus paclitaxel (arm A)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Bevacizumab plus metronomic cyclophosphamide and capecitabine (arm B)
Number of subjects: 147
Study: 24417206

Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 22833186

Group type: COMPARATOR
Intervention: NSAIDs (overall)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 19
Study: 20109986

Group type: EXPERIMENTAL
Intervention: CG care plus tobacco industry and media (IAM) messages
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 87
Study: 18545931

Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 20
Study: 16637070

Group type: EXPERIMENTAL
Intervention: PFTA, EMG Biofeedback, and NMES (Group 3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PFTA and EMG Biofeedback (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PFTA (Group 1)
Number of subjects: 30
Study: 14532920

Group type: EXPERIMENTAL
Intervention: Ertapenem (1 gr/day)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (3.375 gr every six hours)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Ertapenem and Piperacillin/tazobactam
Number of subjects: 623
Study: 11035829

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (fat supplement supplying 26% as fatty acids including DHA, 8%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 20
Study: 8643248

Group type: EXPERIMENTAL
Intervention: Surgery with the adapted esotropic target angle
Number of subjects: 305

Group type: COMPARATOR
Intervention: Surgery with the entry angle
Number of subjects: 305
Study: 1406879

Group type: EXPERIMENTAL
Intervention: Deferoxamine (100 mg/kg/day for 72 hours)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Deferoxamine
Number of subjects: 83
Study: 3899674

Group type: EXPERIMENTAL
Intervention: RU 28318 100 mg (9 alpha‐FHC ingestion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RU 28318 200 mg (aldosterone infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RU 28318 100 mg (furosemide ingestion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RU 28318 300 mg (furosemide ingestion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone (identical doses to RU 28318)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29274022

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 70
Study: 29566555

Group type: EXPERIMENTAL
Intervention: Happiness induction
Number of subjects: 219

Group type: COMPARATOR
Intervention: Fear induction
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control condition (no emotion)
Number of subjects: 219
Study: 29231523

Group type: EXPERIMENTAL
Intervention: Preoperative electroacupuncture at Neiguan (PC 6), Zusanli (ST 36), and Shangjuxu (ST 37) for 20 min at 15 Hz, one day before surgery.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no electroacupuncture).
Number of subjects: 60
Study: 24121364

Group type: EXPERIMENTAL
Intervention: Antecolic reconstruction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Retrocolic reconstruction
Number of subjects: 64
Study: 22398153

Group type: EXPERIMENTAL
Intervention: Internet-based parent training
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 104
Study: 20299089

Group type: EXPERIMENTAL
Intervention: Galardin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine digluconate
Number of subjects: 0
Study: 18658075

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (solid food)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Formula-based ketogenic diet
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 137
Study: 15911669

Group type: EXPERIMENTAL
Intervention: Percutaneous pinning
Number of subjects: 57

Group type: COMPARATOR
Intervention: Immobilisation in a cast
Number of subjects: 57
Study: 12839693

Group type: EXPERIMENTAL
Intervention: rhIL-11 (25 microg/kg body weight, subcutaneously once daily for 7 to 14 days)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: rhIL-11
Number of subjects: 118
Study: 10489789

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 10
Study: 8895208

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Etidocaine
Number of subjects: 75
Study: 1799467

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 58

Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 58
Study: 6226488

Group type: EXPERIMENTAL
Intervention: NET-EN (84-day)
Number of subjects: 3172

Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 3172

Group type: COMPARATOR
Intervention: NET-EN (60-day)
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: NET-EN (60-day) and NET-EN (84-day)
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: All three regimens
Number of subjects: 3172
Study: 30663077

Group type: EXPERIMENTAL
Intervention: Pregabalin 225 mg twice daily for 12 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 28935772

Group type: EXPERIMENTAL
Intervention: Carfilzomib in combination with lenalidomide and dexamethasone (CRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone alone
Number of subjects: 0
Study: 26287536

Group type: EXPERIMENTAL
Intervention: Dezocine
Number of subjects: 665
Study: 24062397

Group type: COMPARATOR
Intervention: Rofecoxib (NSAID)
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: Regular aspirin use
Number of subjects: 896
Study: 22182951

Group type: EXPERIMENTAL
Intervention: Cranial OMM suppression technique
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cranial OMM augmentation technique
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cranial OMM and sham therapy
Number of subjects: 21
Study: 19377182

Group type: EXPERIMENTAL
Intervention: Simulation (Laerdal Virtual I.V. simulator)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional (observed IV insertion on an actual patient)
Number of subjects: 40
Study: 17847940

Group type: EXPERIMENTAL
Intervention: Intercostal catheter analgesia (group A, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intercostal nerve block (group B, n = 40)
Number of subjects: 80
Study: 15588465

Group type: EXPERIMENTAL
Intervention: urinary FSH (uFSH)
Number of subjects: 170

Group type: COMPARATOR
Intervention: recombinant FSH (rFSH)
Number of subjects: 170
Study: 11305826

Group type: EXPERIMENTAL
Intervention: Group I - 20 mg lidocaine plus 25 microg fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group II - 20 mg lidocaine plus 10 microg sufentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group III - 10 mg lidocaine plus 10 microg sufentanil
Number of subjects: 30
Study: 9604053

Group type: EXPERIMENTAL
Intervention: Lumbar spine osteophytes in men
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Hip osteophytes in women
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Osteoporosis at the hip
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Osteoporosis at the lumbar spine
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Osteoporosis in women and men free of spinal osteoarthritis
Number of subjects: 434
Study: 8251960

Group type: EXPERIMENTAL
Intervention: Low-Cost VideoConferencing System (LCVC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face testing
Number of subjects: 0
Study: 3311708

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 400

Group type: COMPARATOR
Intervention: 24 hour continuous stimulation
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 50 hours stimulation
Number of subjects: 400
Study: 31906766

Group type: EXPERIMENTAL
Intervention: Gait training with the Biodex Gait Trainer 3 (a treadmill integrated with music therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional over ground gait training (Control Group)
Number of subjects: 40
Study: 29563779

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (500 mL·d‐1 for 1 month)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (500 mL·d‐1 for 3 months)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control Group (free diet)
Number of subjects: 105
Study: 26876716

Group type: EXPERIMENTAL
Intervention: CCR4 antagonist
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study: 25528251

Group type: EXPERIMENTAL
Intervention: 4.8% tranexamic acid
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: fibrin sponge
Number of subjects: 84

Group type: COMPARATOR
Intervention: no local hemostatic agents
Number of subjects: 84
Study: 24012915

Group type: EXPERIMENTAL
Intervention: 150 min/week exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 225 min/week exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 min/week exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise recommendations
Number of subjects: 0
Study: 21336125

Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (RM) group (positive end‐expiratory pressure 15 cm H2O, peak inspiratory pressure 35‐40 cm H2O for 30 secs)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-recruitment maneuver (NRM) group (ventilation resumed without an RM)
Number of subjects: 59
Study: 18849063

Group type: EXPERIMENTAL
Intervention: 50 mg intramuscular (IM) dimenhydrinate
Number of subjects: 86

Group type: COMPARATOR
Intervention: 2 mL IM saline solution (placebo)
Number of subjects: 86
Study: 17714332

Group type: EXPERIMENTAL
Intervention: Global Mobility Task (GMT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Clinical scales (UPDRS part III and Hoehn & Yahr's score)
Number of subjects: 58
Study: 15054057

Group type: EXPERIMENTAL
Intervention: Turner syndrome subjects
Number of subjects: 14
Study: 11230840

Group type: EXPERIMENTAL
Intervention: Omapatrilat (high-dose groups)
Number of subjects: 48
Study: 9489981

Group type: EXPERIMENTAL
Intervention: Center 1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Center 2
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Center 3
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Center 4
Number of subjects: 99
Study: 8565032

Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 30 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 60 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core
Number of subjects: 207

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 207
Study: 2350875

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg intravenously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 444346

Group type: EXPERIMENTAL
Intervention: Althesin and nitrous oxide in oxygen
Number of subjects: 170

Group type: COMPARATOR
Intervention: Thiopentone and nitrous oxide in oxygen and halothane
Number of subjects: 170
Study: 30783173

Group type: EXPERIMENTAL
Intervention: Elemental feed
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Polymeric feed
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard feeds
Number of subjects: 95
Study: 28938283

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 25851635

Group type: COMPARATOR
Intervention: Calcium citrate fasting
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium citrate with a meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fortified juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dairy product meal
Number of subjects: 10
Study: 26383579

Group type: EXPERIMENTAL
Intervention: High-speed handpiece and minimally invasive extraction (Group A)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Traditional method (Group B)
Number of subjects: 83
Study: 24277399

Group type: EXPERIMENTAL
Intervention: Early oral feeding group
Number of subjects: 70
Study: 20835716

Group type: EXPERIMENTAL
Intervention: Intermittent pneumoperitoneum (IPP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional conduct (CPP)
Number of subjects: 51
Study: 18499623

Group type: EXPERIMENTAL
Intervention: PERI group receiving intraoperative and postoperative ketamine (2 microg x kg(‐1) x min(‐1) after a 0.5 mg/kg bolus)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: INTRA group receiving intraoperative ketamine (2 microg x kg(‐1) x min(‐1) after a 0.5 mg/kg bolus)
Number of subjects: 81

Group type: COMPARATOR
Intervention: CTRL group receiving placebo
Number of subjects: 81
Study: 16542203

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg day(-1) and Olanzapine 15 mg day(-1) coadministration (LTG + OLZ group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lamotrigine 200 mg day(-1) with placebo (LTG group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo with Olanzapine 15 mg day(-1) (OLZ group)
Number of subjects: 44
Study: 12716329

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD) - Emdogain (U Biora AB Malm, Sweden)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Guided Tissue Regeneration (GTR) - ePTFE membranes (Gore‐Tex W.L. Gore and Associates, Flagstaff, AZ, USA)
Number of subjects: 98
Study: 11113227

Group type: EXPERIMENTAL
Intervention: Cladribine (0.7 mg/kg and 2.1 mg/kg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 9762661

Group type: EXPERIMENTAL
Intervention: CSF oligoclonal IgG bands
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Virus-specific oligoclonal IgG antibodies
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CSF Myelin Basic Protein-like material
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CSF markers analysis
Number of subjects: 27
Study: 2841177

Group type: EXPERIMENTAL
Intervention: White Bread (WB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: French Toast (FT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bran-Enriched French Toast (BFT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral Glucose Load
Number of subjects: 12
Study: 30511958

Group type: EXPERIMENTAL
Intervention: Twister wrap orthosis (TWO) in addition to conventional physical therapy and ankle foot orthosis (AFO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy and ankle foot orthosis (AFO)
Number of subjects: 30
Study: 26186485

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) with 90% avoidance/10% approach for smoking stimuli and 10% avoidance/90% approach for neutral stimuli
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham training with 50% avoidance/50% approach for smoking and neutral stimuli
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both CBM and sham
Number of subjects: 60
Study: 24169284

Group type: EXPERIMENTAL
Intervention: Allitridi capsules (120 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 21174182

Group type: EXPERIMENTAL
Intervention: Multimodal analgesic approach (MMA) including paravertebral blocks with 0.5% ropivacaine, celecoxib (400 mg po prior to surgery and 200 mg po bid for seven days), and ketamine (10 mg iv)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodal analgesic approach (MMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) alone
Number of subjects: 0
Study: 18511476

Group type: EXPERIMENTAL
Intervention: Topical NSAIDs
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Oral NSAIDs
Number of subjects: 585
Study: 17154784

Group type: EXPERIMENTAL
Intervention: Attended distractor features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response compatibility effect
Number of subjects: 0
Study: 14526195

Group type: EXPERIMENTAL
Intervention: Aspen TLSO
Number of subjects: 10

Group type: COMPARATOR
Intervention: Boston Body Jacket
Number of subjects: 10

Group type: COMPARATOR
Intervention: CAMP TLSO
Number of subjects: 10
Study: 10896696

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A; Dysport)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8716209

Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy
Number of subjects: 12